Abstract
Breast cancer (BC) remains a common life-threatening condition that has undergone extensive scientific and clinical investigation over the past two decades. Despite expanding knowledge of genetics, prognostic factors, and biology, as well as advances in surgical management, adjuvant chemotherapy (CT), and radiotherapy, many women will die from progressive, metastatic breast cancer (MBC). Over the past 10 yr, many investigators have studied the role of high-dose chemotherapy (HDCT) with hematopoietic stem cell support. Many phase II high-dose regimens have been explored, and, recently, some small randomized clinical trials have been undertaken. Despite this interest, questions remain concerning the exact role of this modality in therapy for BC. The development, rationale, and results of this modality are reviewed here, and the appropriate timing of applying this therapy in the treatment of MBC are addressed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Frei E Ill, Teicher BA, Holden SA, et al. Effect of alkylating agent dose: studies and possible clinical correlation, Cancer Res, 48 (1988) 6417–6432.
Teicher BA, Cucci CA, Lee JB, et al. Alkylating agents: in vitro studies of cross resistance patterns in human cell lines, Cancer Res, 46 (1986) 4379–4383.
Henderson IC, Hayes DF, and Gelman R. Dose-response in the treatment of breast cancer: a critical review, J. Clin. Oncol., 6 (1988) 1501–1515.
Hyrniuk W and Bush H. Importance of dose intensity in chemotherapy of metastatic breast cancer, J. Clin. Oncol., 2 (1984) 1281–1288.
Peters WP, Eder JP, Henner WP, et al. High-dose combination alkylating agents with autologous bone marrow support: a phase I study, J. Clin. Oncol., 4 (1986) 646–654.
Antman K, Eder JP, Elias A, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Institute/Beth Israel Hospital Experience, Cancer Treat. Rep., 71 (1987) 119–125.
Williams SF, Bitran J, Kaminer L, et al. Phase I—II study of bialkylator chemotherapy, high dose thiopeta and cyclophosphamide with autologous bone marrow reinfusion in patients with refractory cancer, J. Clin. Oncol., 5 (1987) 260–265.
Slease RB, Benear JB, Selby GB et al. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors, J. Clin. Oncol., 6 (1988) 1314–1320.
Eder JP, Antman K, and Elias A. Cyclophosphamide and thiotepa with autologous bone marrow transplant in patients with solid tumors, J. Natl. Cancer Inst., 80 (1988) 1221–1226.
Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer, J. Clin. Oncol., 6 (1988) 1368–1376.
Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America, J. Clin. Oncol., 15 (1997) 1870–1879.
Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agent XIII. On the criteria and kinetics associated with “curability” of experimental leukemia, Cancer Chemother. Rep., 35 (1964) 1–111.
Norton L and Simon R. Tumor size, sensitivity to therapy and the design of treatment schedules, Cancer Treat. Rep., 61 (1977) 1307–1317.
Norton L. Gomperztian model of human breast cancer growth, Cancer Res, 48 (1988) 7067–7071.
Goldie J. and Goldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat. Rep., 63 (1979) 1727–1773.
Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents in bone marrow support as initial treatment for metastatic breast cancer, J. Clin. Oncol., 6 (1988) 1368–1376.
Bezwoda WR, Seymour L, and Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial, J. Clin. Oncol., 13 (1995) 2483–2489.
Mick R, Begg C, Antman K, et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res. Treat., 13 (1989) 33–38.
Bezwoda WR. High dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice, Cancer Chemother. Pharmacol., 40 (Suppl) (1997) S79 - S87.
Lazarus HM. Hematopoietic progenitor cell transplantation in breast cancer: current status and future direction, Cancer Invest, 16 (1998) 102–126.
Rahman ZU, Frye DK, Buzdar AU. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard dose doxorubicin containing chemotherapy in patients with metastatic breast cancer, J. Clin. Oncol.,15 (1997) 31713177.
Dunphy FR, Sptizer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support, J. Clin. Oncol., 8 (1990) 1207–1216.
Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study, J. Clin. Oncol., 12 (1994) 37–44.
Ghalie R, Williams SF, Valentino LA, Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer, Biol. Blood Marrow Transplant., 1 (1995) 40–46.
Bitran JD, Samuels B, Klein L, et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer, Bone Marrow Transplant, 17 (1996) 157–162.
Peters WP, Jones RB, Vredenburgh J. Large prospective randomized trial of high dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy, Proc. Am. Soc. Clin. Oncol.,15 (1996) 121(Abstract).
Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells, Blood, 84 (1994) 380–383.
Brenner MK, Rill DR, Moan RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation, Lancet, 341 (1993) 85–86.
Brockstein BE, Ross AA, Moss TJ, et al. Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage patients undergoing high-dose chemotherapy, J. Hematother., 5 (1996) 617–624.
Lazarus HM, Rowe JM, and Goldstone AH. Does in vitro purging improve the outcome after autologous bone marrow transplantation? J. Hematother., 2 (1994) 457–466.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Williams, S.F. (2000). What Is the Optimal Timing of Autologous Transplantation for Metastatic Breast Cancer?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_14
Download citation
DOI: https://doi.org/10.1007/978-1-59259-657-7_14
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9812-7
Online ISBN: 978-1-59259-657-7
eBook Packages: Springer Book Archive